Alternatives to HRT in prevention and treatment

Abe, 1988, 1α, 25-Dihydroxy-22-oxavitamin D3: a new synthetic analogue of vitamin D3 having potent differentiation-producing activity without inducing hypercalcaemia in vivo and in vitro, 309 Aloia, 1981, Changes in body composition following therapy for osteoporosis with methandrostenelone, Metabolism, 30, 1076, 10.1016/0026-0495(81)90050-0 Aloia, 1988, Calcitriol in the treatment of postmenopausal osteoporosis, American Medical Journal, 84, 401, 10.1016/0002-9343(88)90259-8 Agnusdei, 1990, Metabolic and clinical effects of inriflavone in postmenopausal osteoporotic patients, 2159 Avrimides, 1976, Paget's disease of bone: observations after cessation of long term synthetic salmon calcitonin treatment, Journal of Clinical Endocrinology and Metabolism, 42, 459, 10.1210/jcem-42-3-459 Baud, 1988, Biophysical studies of bone mineral in biopsies of osteoporotic patients before and after long-term treatment with fluoride, Bone, 9, 361, 10.1016/8756-3282(88)90117-2 Beneton, 1991, Stanozalol stimulates remodelling of trabecular bone and the net formation of bone at the endocortical surface, Clinical Science, 81, 543, 10.1042/cs0810543 Bishop, 1990, Oral toxicity of 1α-hydroxyvitamin D2 (1αOHD2) in rats, Journal of Bone and Mineral Research, 5, 196 Buckle, 1989, A 3 year study of sodium fluoride treatment on vertebral fracture incidence in osteoporosis, Journal of Bone and Mineral Research, 4, S186 Canonico, 1990, Effects of ipriflavone on experimental models of bone resorption and synthesis, 2133 Chesnut, 1977, Effect of methandrostenolone on postmenopausal bone wasting as assessed by changes in total bone mineral mass, Metabolism, 26, 267, 10.1016/0026-0495(77)90073-7 Chesnut, 1983, Stanozolol in postmenopausal osteoporosis: therapeutic efficacy and possible mechanisms of action, Metabolism, 32, 571, 10.1016/0026-0495(83)90027-6 Chow, 1987, Effect of two randomised exercise programmes on bone mass of healthy women, British Medical Journal, 295, 1441, 10.1136/bmj.295.6611.1441 Dalsky, 1988, Weight-bearing exercise training and lumbar bone mineral content in postmenopausal women, Annals of Internal Medicine, 108, 824, 10.7326/0003-4819-108-6-824 Dawson-Hughes, 1990, A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women, New England Journal of Medicine, 323, 878, 10.1056/NEJM199009273231305 Duursma, 1987, Responders and non-responders after fluoride therapy in osteoporosis, Bone, 8, 131, 10.1016/8756-3282(87)90011-1 Ettinger, 1987, Postmenopausal bone loss is prevented by treatment with low dosage estrogen with calcium, Annals of Internal Medicine, 106, 40, 10.7326/0003-4819-106-1-40 Farley, 1988, The anti-bone-resorptive agent calcitonin also acts in vitro to directly increase bone formation and bone cell proliferation, Endocrinology, 123, 159, 10.1210/endo-123-1-159 Foster, 1964, Thyroid origin of calcitonin, Nature, 202, 1303, 10.1038/2021303a0 Foster, 1969, In vivo effects of thyrocalcitonin on bone, 173 Friedman, 1965, Thyrocalcitonin: inhibitor of bone resorption in tissue culture, Science, 150, 1465, 10.1126/science.150.3702.1465 Frost, 1979, Treatment of osteoporosis by manipulation of coherent bone cell populations, Clinics in Orthopaedics and Related Research, 143, 227 Gallagher, 1990, Action of 1,25-dihydroxyvitamin D3 on calcium balance and bone turnover and its effects on vertebral fracture rate, Metabolism, 39, 30, 10.1016/0026-0495(90)90269-I Gallagher, 1989, Effect of increasing doses of 1-α hydroxyvitamin D2 on serum and urine calcium in postmenopausal osteoporosis, Journal of Bone and Mineral Research, 4 Gennari, 1981, Acute effects of salmon, human and porcine calcitonin on plasma calcium and cyclic AMP levels in man, Current Therapeutics Research, 30, 1024 Girgis, 1980, Immunoreactive human calcitonin-like molecule in the nervous systems of protochordates and a cyclostome, Myxine, Journal of Endocrinology, 87, 375, 10.1677/joe.0.0870375 Glowacki, 1986, Factors that stimulate bone formation, 93 Godsland, 1986, Insulin action and dynamics modelling in patients taking the anabolic steroid methandienone (Dianabol), Clinical Science, 71, 665, 10.1042/cs0710665 Goldfield, 1972, Synthetic salmon calcitonin: treatment of Paget's disease and osteogenesis imperfecta, Journal of the American Medical Association, 221, 1127, 10.1001/jama.1972.03200230015004 Greenberg, 1986, Effects of estradiol and progesterone on calcitonin secretion, Endocrinology, 118, 2594, 10.1210/endo-118-6-2594 Gruber, 1984, Long-term calcitonin therapy in postmenopausal osteoporosis, Metabolism, 33, 295, 10.1016/0026-0495(84)90187-2 Guesens, 1986, Long-term effect of nandrolone decanoate, 1α-hydroxyvitamin D3 or intermittent calcium infusion therapy on bone mineral content, bone remodeling and fracture rate in symptomatic osteoporosis: a double-blind controlled study, Journal of Bone and Mineral Research, 1, 347 Heaney, 1987, The role of nutrition in prevention and management of osteoporosis, Clinics in Obstetrics and Gynecology, 50, 833, 10.1097/00003081-198712000-00007 Hedlund, 1989, Increased incidence of hip fracture in women treated with sodium fluoride, Journal of Bone and Mineral Research, 4, 223, 10.1002/jbmr.5650040214 Hesch, 1989, Increase of vertebral bone density by combination therapy with pulsatile 1–38 PTH and sequential addition of calcium nasal spray in osteoporotic patients, Calcified Tissue International, 44, 176, 10.1007/BF02556561 Hurley, 1987, Axial and appendicular bone mineral density in patients with long-term deficiency or excess of calcitonin, New England Journal of Medicine, 317, 537, 10.1056/NEJM198708273170904 Kanis, 1989, Calcium supplementation of the diet—II, British Medical Journal, 298, 205, 10.1136/bmj.298.6668.205 Kanis, 1989, Calcium supplementation of the diet—I, British Medical Journal, 298, 137, 10.1136/bmj.298.6667.137 Kraenzlin, 1990, Fluoride pharmacokinetics in good and poor responders to fluoride therapy, Journal of Bone and Mineral Research, 5, S49 Lloyd, 1988, Collegiate women athletes with, Obstetrics and Gynaecology, 72, 639 DeLuise, 1970, Inactivation and degradation of porcine calcitonin by rat liver, and relative stability of salmon calcitonin, Journal of Endocrinology, 48, 181, 10.1677/joe.0.0480181 McDermott, 1983, Reduced bone mineral content in totally thyroidectomized patients: possible effects of calcitonin deficiency, Journal of Clinical Endocrinology and Metabolism, 56, 936, 10.1210/jcem-56-5-936 MacIntyre, 1988, Calcitonin for prevention of postmenopausal bone loss, Lancet, i, 900, 10.1016/S0140-6736(88)91712-6 Mamelle, 1988, Risk-benefit ratio of sodium fluoride treatment in primary vertebral osteoporosis, Lancet, ii, 361, 10.1016/S0140-6736(88)92834-6 Marie, 1986, Mechanisms underlying the effects of phosphate and calcitonin on bone histology in postmenopausal osteoporosis, Bone, 7, 17, 10.1016/8756-3282(86)90147-X Meunier, 1990, Fluoride salts and osteoporosis, 1308 Milhaud, 1965, Eludé de mecanisme de l'action hypocalcemiante de la thyrocalcitonine, Comptes Rendus de l'Académie des Sciences (Paris), 261, 813 Neer, 1990, Treatment of postmenopausal osteoporosis with daily parathyroid hormoneplus calcitrol, 1314 O'Doherty, 1990, A comparison of the acute effects of subcutaneous and intranasal calcitonin, Clinical Science, 78, 215, 10.1042/cs0780215 Ott, 1989, Calcitriol treatment is not effective in postmenopausal osteoporosis, Annals of Internal Medicine, 110, 267, 10.7326/0003-4819-110-4-267 Overgaard, 1989, Nasal calcitonin for the treatment of established osteoporosis, Clinical Endocrinology, 30, 435, 10.1111/j.1365-2265.1989.tb00443.x Overgaard, 1992, Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study, British Medical Journal, 305, 556, 10.1136/bmj.305.6853.556 Rasmussen, 1980, Effect of combined therapy with phosphate and calcitonin on bone volume in osteoporosis, Metabolic Bone Disease and Related Research, 2, 107, 10.1016/0221-8747(80)90006-5 Reeve, 1980, Anabolic effects of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial, British Medical Journal, 280, 1340, 10.1136/bmj.280.6228.1340 Reginster, 1987, 1-year controlled randomised trial of prevention of early postmenopausal bone loss by intranasal calcitonin, Lancet, ii, 1481, 10.1016/S0140-6736(87)92619-5 Reginster, 1989, Prevention of postmenopausal bone loss by tiludronate, Lancet, ii, 1469, 10.1016/S0140-6736(89)92927-9 Reid, 1988, Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD), Lancet, i, 143, 10.1016/S0140-6736(88)92721-3 Rich, 1961, Effect of sodium fluoride on calcium metabolism of human beings, Nature, 191, 184, 10.1038/191184a0 Riggs, 1982, Evidence for the etiological heterogenicity of involutional osteoporosis, 3 Riggs, 1982, Effect of the fluoride/calcium regimen on vertebral fracture occurrence in postmenopausal osteoporosis: comparison with conventional therapy, New England Journal of Medicine, 306, 446, 10.1056/NEJM198202253060802 Riggs, 1990, Effect of the fluoride treatment on the fracture in postmenopausal women with osteoporosis, New England Journal of Medicine, 322, 802, 10.1056/NEJM199003223221203 Russell, 1974, Diphosphonates in Paget's disease, Lancet, i, 894, 10.1016/S0140-6736(74)90347-X Russell, 1990, Humoral and local factors affecting bone formation and resorption, 1 Sato, 1991, Bisphosphonate action: alendronate localisation in rat bone and effects on osteoclastic ultrastructure, Journal of Clinical Investigation, 88, 2095, 10.1172/JCI115539 Slovik, 1981, Short-term effects of synthetic human parathyroid hormone (1–34) administration on bone mineral metabolism in osteoporotic patients, Journal of Clinical Investigation, 68, 1261, 10.1172/JCI110372 Stevenson, 1980, The structure and function of calcitonin, Investigative Cell Pathology, 3, 187 Stevenson, 1981, Pharmacology and therapeutic use of calcitonin, Drugs, 21, 257, 10.2165/00003495-198121040-00002 Stevenson, 1981, Calcitonin and the calcium-regulating hormones in postmenopausal women: effect of oestrogens, Lancet, i, 693, 10.1016/S0140-6736(81)91973-5 Stevenson, 1986, Osteoporosis with hip fracture: changes in calcium regulating hormones, European Journal of Clinical Investigation, 16, 357, 10.1111/j.1365-2362.1986.tb01009.x Stevenson, 1989, Determinants of bone density in normal women: risk factors for future osteoporosis?, British Medical Journal, 298, 924, 10.1136/bmj.298.6678.924 Stevenson, 1990, Calcitonin gene peptides and bone metabolism, 63 Storm, 1990, Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis, New England Journal of Medicine, 322, 1265, 10.1056/NEJM199005033221803 Stout, 1990, Insulin and atheroma: 20-yr perspective, Diabetes Care, 13, 631, 10.2337/diacare.13.6.631 Sturtridge, 1977, Long-term treatment of Paget's disease of bone with salmon calcitonin, Journal of the Canadian Medical Association, 117, 1031 Szilklai, 1985, The effect of flavone treatment on human otosclerotic ossicle organ cultures, Archives of Oto-rhino-laryngology, 242, 67, 10.1007/BF00464409 Szocsik, 1990, Ipriflavone in the prevention of postmenopausal osteoporosis, 2164 Taggart, 1982, Deficient calcitonin response to calcium stimulation in post-menopausal osteoporosis, Lancet, i, 475, 10.1016/S0140-6736(82)91451-9 Thamsborg, 1990, The effect of different doses of nasal salmon calcitonin on plasma cyclic AMP and serum ionised calcium, Calcified Tissue International, 46, 5, 10.1007/BF02555817 Tillyard, 1992, Treatment of postmenopausal osteoporosis with calcitriol or calcium, New England Journal of Medicine, 326, 357, 10.1056/NEJM199202063260601 Valkema, 1987, A four year continuous gain in bone mass in APD-treated osteoporosis, 836 Watts, 1990, Intermittent cyclical etidronate treatment of postmenopausal osteoporosis, New England Journal of Medicine, 323, 73, 10.1056/NEJM199007123230201 Wickham, 1989, Dietary calcium, physical activity, and the risk of hip fracture: a prospective study, British Medical Journal, 299, 889, 10.1136/bmj.299.6704.889 Yamazaki, 1986, Calcitonin secreting properties of ipraflavone in the presence of oestrogen, Life Sciences, 38, 1535, 10.1016/0024-3205(86)90492-3